Trial Brazil Insurance Broker
Protocol-Led Coverage in Clinical Research
Mariana Bontorin, CEO
Clinical Research Insurance Brokerage Services in Latin America
Clinical research insurance brokerage services help sponsors and research organizations secure coverage for trial-related risks. With a focus on policy guidance, regulatory alignment, risk assessment and claims support, they support safer study execution and more reliable research protection.
Solutions
Clinical research in Latin America is becoming more structured as protocols, regulatory expectations and participant protections continue to evolve. Within that environment, insurance coverage only works when it aligns with protocol requirements, local regulations and social security systems. Trial Brazil Insurance Broker operates within that space, connecting coverage directly to research obligations and participant risk.
State of Industry
Latin America's Clinical Research Landscape: Tailored Insurance Brokerage Solutions
The expansion of global clinical research has significantly increased demand for specialized insurance brokerage services to manage risk and ensure effective regulatory compliance. Clinical trials today are conducted across multiple countries, involve diverse patient populations, and operate under strict legal and ethical frameworks. These complexities introduce a wide range of risks, including participant injury, protocol deviations, and liability exposure. As pharmaceutical, biotechnology, and medical device companies continue to invest in research and development, securing appropriate insurance coverage has become a critical priority.
Deep Dive
Choosing Insurance Brokerage for Clinical Research
Insurance is now an essential part of every clinical study. Sponsors, research institutions, and CROs work in markets where rules and insurer preferences can change quickly or slowly. A policy that appears sufficient on paper may fall short for trials involving pediatric surgery, vaccine development, new cancer treatments, or experimental therapies with unknown risks. In these situations, choosing the right broker is more important than just looking at price. Executives acquiring brokerage support should treat the decision less as a placement exercise and more as a test of whether the broker can support you through claims, unexpected delays, or regulatory reviews.
Leadership Perspective
Biogen
Shaping Brazil's Future in Global Clinical Research
Giovanni Guzzo, Sr. Clinical Country and Site Lead, Ass. Director
Giovanni Guzzo is a clinical research leader, Sr. Clinical Country and Site Lead as an Associate Director at Biogen. With a PharmD, MSc and PhD in Pharmacokinetics and Bioequivalence, he brings deep scientific rigor and strategic insight to complex clinical trials. From site management to patient recruitment and regulatory strategy, Guzzo is known for delivering results that accelerate timelines, uphold compliance and enhance outcomes, driving innovation where it matters most at the patient level.
Clinical Research Insurance Brokerage Services in Latin America News
Trial Growth in Latin America Raises Demand for Specialist Insurance Brokerage
Wednesday, July 29, 2026
Clinical research insurance brokerage services in Latin America are gaining stronger relevance as sponsors, CROs and medical device developers expand trial activity across the region. Latin America offers patient access, experienced investigators and competitive research costs, but sponsors also need insurance programs that satisfy local regulators and ethics committees before studies can begin.
The region’s clinical research market is expanding. One 2026 market estimate values the Latin America clinical trials market at USD 4.44 billion in 2026 and projects it to reach USD 11.86 billion by 2036, at a CAGR of 10.32 percent. Another outlook expects the Latin America pharmaceutical CRO market to reach USD 5.48 billion by 2033, with a CAGR of 7 percent from 2026 to 2033.
This growth increases the need for brokerage support because clinical trial insurance is not a generic liability purchase. A policy must match the study protocol, participant risk profile, country requirements, investigator obligations and sponsor structure. A sponsor running trials in Brazil, Mexico or Argentina may face different documentation expectations from each authority or ethics committee.
The regulatory landscape of Latin America is also divided. A 2026 regional regulatory guide lists different approval timelines across countries, including 60 to 90 days for ANVISA in Brazil, 42 to 62 days for ANMAT in Argentina, 120 to 280 days for INVIMA in Colombia and 180 to 220 days for COFEPRIS in Mexico.
That variation makes brokerage coordination more valuable. The sponsor requires the issuance of the policy in the correct jurisdiction, along with the right limitations, insured and translation where necessary. This means that there may be a delay in getting acceptable evidence of the policy.
Specialist brokers also help sponsors understand coverage language. Clinical trial insurance in Latin America may need to address participant injury, extracontractual civil liability, defense costs, policy period, retroactive dates and deductible structure. Bioaccess notes that many authorities and ethics committees require policies or certified translations in Spanish and that sponsors need brokers familiar with country-specific documentation requirements.
The business risk is practical. While a multinational corporation may be covered under a master policy, there could be a need for certificates or admitted policies from local committees. A broker that understands both global programs and local evidence requirements can prevent avoidable back-and-forth during startup.
Clinical research insurance brokerage in Latin America is moving toward being trial-startup facilitators. Their success will depend on how effective they are at helping the sponsor get appropriate coverage, while minimizing insurance delays in the region’s increasing clinical research field.
Country-Specific Insurance Rules Make Local Brokerage Expertise Critical
Wednesday, July 29, 2026
Clinical research insurance brokerage services in Latin America are being shaped by the fact that trial insurance requirements vary by country and cannot always be solved through a single global policy. Sponsors conducting multi-country studies must coordinate coverage across local regulators, ethics committees, hospitals and research sites.
Countries from Latin America like Brazil, Mexico, Argentina, Chile and Colombia typically demand compulsory insurance for any clinical trials performed in their respective regions. The limit of insurance is usually based on international norms and risks involved. One insurance-cost analysis describes typical limits in the USD 1 million to USD 5 million range per trial, although requirements can vary by country and protocol.
This creates a brokerage challenge. A sponsor may want one efficient regional program, but each country can require different wording, filings, insured-party treatment or documentation. A policy that satisfies one committee may be rejected by another if the language, coverage territory or participant-injury provisions are unclear.
Brazil is a strong example of why local knowledge matters. Clinical trial submissions involving ANVISA can require careful coordination across regulatory review and ethics review. Clinical trials involving ANVISA require special attention to regulatory and ethics reviews. The ANMAT in Argentina, the COFEPRIS in Mexico, the ISP in Chile, and the INVIMA in Colombia all have distinct processes that must be adhered to.
Insurance brokers serving this market need to work closely with CROs and regulatory teams. The insurance certificate must often be ready at the right point in the submission sequence. If coverage evidence is incomplete or not accepted, a study can lose weeks before the first site is activated.
Language is another practical issue. Policy language may need to be issued in Spanish or supported by a certified translation. In Brazil, Portuguese documentation may be needed. Sponsors who think that the English language global certificate will be accepted in all jurisdictions face delays.
Another task of the broker involves coordinating named insureds. It is normal for the sponsor to be considered the major insured, but other persons such as the chief risk officer or the institution might have to be included according to contractual stipulations.
Global carriers are emphasizing the cross-border nature of trial risk. Chubb states that sponsors organizing clinical trials across borders face evolving liabilities and need coordinated global clinical trial insurance programs.
The strongest brokers will likely be those that understand both life sciences liability and Latin American trial operations. They must translate insurance structures into regulatory-ready documents while helping sponsors avoid overbuying, underinsuring or missing local conditions.
Clinical research insurance brokerage services in Latin America are becoming country-specific compliance partners. Their value will come from helping sponsors navigate local rules without losing regional efficiency.
Complex Trial Models Increase the Need for Risk-Advisory Brokerage
Wednesday, July 29, 2026
Clinical research insurance brokerage services in Latin America are moving beyond policy placement as trial designs become more complex. Sponsors are running oncology, rare disease, device, decentralized and first-in-human studies across regional markets, which changes the risk profile and insurance needs before enrollment begins.
The region is attracting more research activity because sponsors want recruitment access and diversified trial footprints. Towards Healthcare estimates that the Latin America clinical trials market will grow from USD 5.0 billion in 2026 to USD 9.17 billion by 2035, while the region’s pharmaceutical contract manufacturing and research services market is forecast to grow from USD 24.09 billion in 2026 to USD 43.99 billion by 2035.
This expansion increases demand for brokers that can advise on trial risk rather than merely obtain a certificate. A low-risk observational study, a device implantation trial and an early-stage oncology study do not create the same insurance exposure. Coverage limits, exclusions and policy wording should reflect participant risk and sponsor obligations.
Operational complexity also matters. A trial may involve several countries, multiple CRO partners, public hospitals, private sites and different investigator contracts. The insurance program must align with indemnity clauses and local legal expectations. When those documents conflict, startup teams can face delays or coverage uncertainty.
Clinical trials are already exposed to operational risk. A 2026 machine-learning study on trial success notes that clinical trials involve high costs, long timelines and substantial operational risk, with success depending on initiation, conduct, recruitment targets and protocol completion. Insurance brokerage cannot solve all these risks, but it can reduce uncertainty around participant injury liability and sponsor financial exposure.
Protection of participants is crucial. The insurance should allow for procedures for providing compensation in case of injury caused by participation in the study. In jurisdictions where the knowledge about clinical trials might not be as widespread as elsewhere, proper insurance documentation will increase the confidence of ethics boards, researchers and patients.
The broker should also ensure that sponsors do not have any discrepancies between the global risk management and the local one. The master policy might provide comprehensive cover, but it does not mean that local laws, ethics reviews or site agreements require certain documentation. Proper brokerage will synchronize these three before it becomes an issue.
Decentralized elements may add new questions. Remote visits, home nursing, device shipment and digital monitoring can create exposures outside the traditional research site. Brokers may need to review whether coverage extends to these activities and whether vendors should be added or separately insured.
The next phase of clinical research insurance in Latin America will likely favor brokers that operate as risk advisors inside the trial-startup process. Sponsors need support that connects insurance, contracts and regulatory submissions.
Clinical research insurance brokerage services in Latin America are becoming part of trial-risk management. Their strongest value will come from helping sponsors protect participants, satisfy local requirements and keep complex studies moving toward activation.
Clinical Research Insurance Brokerage Services in Latin America Info
Q1
What Do Top Clinical Research Insurance Brokerage Services Provide?
Top Clinical Research Insurance Brokerage Services help pharmaceutical companies, biotechnology firms, contract research organizations (CROs), research institutions and trial sponsors secure insurance coverage for clinical studies. These services identify appropriate insurance solutions, coordinate policy placement and help ensure coverage meets the regulatory and contractual requirements of every country where a trial is conducted. They also support organizations in managing participant protection, liability and the risks associated with multinational research programs.
Q2
What Services Are Typically Included in Clinical Research Insurance Brokerage?
Top Clinical Research Insurance Brokerage Services commonly include clinical trial liability insurance placement, multinational insurance program coordination, regulatory compliance support, policy administration, certificate management, claims assistance, contract review and risk assessment. Many brokers also help sponsors navigate country-specific insurance requirements and structure coverage for studies conducted across multiple jurisdictions and trial phases.
Q3
Why Is Demand for Top Clinical Research Insurance Brokerage Services Growing?
Demand for Top Clinical Research Insurance Brokerage Services continues to increase as clinical research expands across international markets and regulatory requirements become more complex. Sponsors are conducting more multicountry studies that require locally compliant insurance, coordinated documentation and consistent risk management. At the same time, advances in biotechnology, decentralized clinical trials and global research collaborations are increasing the need for brokers with specialized life sciences expertise.
Q4
How Are Top Clinical Research Insurance Brokerage Services Evaluated?
Choosing among Top Clinical Research Insurance Brokerage Services involves more than comparing insurance providers. Organizations typically evaluate a broker’s expertise in life sciences and clinical research, knowledge of regional regulations, global placement capabilities, insurer relationships, responsiveness, claims support and ability to manage multinational insurance programs. Experience with complex study protocols, documentation requirements and long-term program administration is also an important consideration.
Q5
What Value Do Clinical Research Insurance Brokerage Services Create?
Top Clinical Research Insurance Brokerage Services help reduce operational risk by ensuring the right insurance coverage is in place before participant enrollment begins. Effective brokerage support helps organizations meet regulatory requirements, reduce administrative delays, accelerate study start-up and protect sponsors, investigators and research institutions against trial-related liabilities. This allows clinical studies to progress more smoothly while helping manage financial and legal risk throughout the research lifecycle.
Q6
How Are Innovation and Expertise Shaping Clinical Research Insurance Brokerage Services?
Today’s Top Clinical Research Insurance Brokerage Services are being strengthened by digital policy management, automated certificate generation, centralized documentation platforms and improved coordination of multinational insurance programs. Even with these technological advances, specialized expertise remains essential because clinical research insurance requires a deep understanding of evolving regulations, participant protection requirements, multinational liability exposures and life sciences risk management. Combining technology with industry knowledge enables brokers to support increasingly complex global clinical research programs.
